Future of neuroprotection in Parkinson's disease (Q40693116)

22 September 2017

title

Future of neuroprotection in Parkinson's disease (English)

1 reference

22 September 2017

1 reference

M Naoi

1 reference

22 September 2017

W Maruyama

series ordinal

1 reference

22 September 2017

publication date

1 October 2001

1 reference

Parkinsonism and Related Disorders

22 September 2017

1 reference

inferred from page(s)

published in

1 reference

22 September 2017

1 reference

22 September 2017

1 reference

22 September 2017

page(s)

139-145

1 reference

Mutation in the alpha-synuclein gene identified in families with Parkinson's disease

22 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2801%2900028-1

7 January 2021

Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2801%2900028-1

7 January 2021

Advances in our understanding of the mechanisms of the neurotoxicity of MPTP and related compounds

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2801%2900028-1

7 January 2021

Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2801%2900028-1

7 January 2021

DATATOP: a multicenter controlled clinical trial in early Parkinson's disease. Parkinson Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2801%2900028-1

7 January 2021

Cell death mechanisms in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2801%2900028-1

7 January 2021

Apoptosis in the pathogenesis and treatment of disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2801%2900028-1

7 January 2021

Rescue of dying neurons: A new action for deprenyl in MPTP parkinsonism

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2801%2900028-1

7 January 2021

Deprenyl protects dopamine neurons from the neurotoxic effect of 1-methyl-4-phenylpyridinium ion.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2801%2900028-1

7 January 2021

An endogenous dopaminergic neurotoxin, N-methyl-(R)-salsolinol, induces DNA damage in human dopaminergic neuroblastoma SH-SY5Y cells

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2801%2900028-1

7 January 2021

(-)-Deprenyl protects human dopaminergic neuroblastoma SH-SY5Y cells from apoptosis induced by peroxynitrite and nitric oxide

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2801%2900028-1

7 January 2021

Dopamine-derived endogenous 1(R),2(N)-dimethyl-6,7-dihydroxy- 1,2,3,4-tetrahydroisoquinoline, N-methyl-(R)-salsolinol, induced parkinsonism in rat: biochemical, pathological and behavioral studies

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2801%2900028-1

7 January 2021

Apoptosis induced by an endogenous neurotoxin, N-methyl(R)salsolinol, is mediated by activation of caspase 3.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2801%2900028-1

7 January 2021

Enantio-specific induction of apoptosis by an endogenous neurotoxin, N-methyl(R)salsolinol, in dopaminergic SH-SY5Y cells: suppression of apoptosis by N-(2-heptyl)-N-methylpropargylamine

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2801%2900028-1

7 January 2021

Alkaloids in mammalian tissues. 2. Synthesis of (+)- and (-)-1-substituted-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinolines

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2801%2900028-1

7 January 2021

Aliphatic propargylamines: potent, selective, irreversible monoamine oxidase B inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2801%2900028-1

7 January 2021

Glyceraldehyde-3-phosphate dehydrogenase, the putative target of the antiapoptotic compounds CGP 3466 and R-(-)-deprenyl

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2801%2900028-1

7 January 2021

Monoamine oxidase B inhibitor selegiline protects young and aged rat peripheral sympathetic neurons against 6-hydroxydopamine-induced neurotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2801%2900028-1

7 January 2021

Protection against DSP-4-induced neurotoxicity by deprenyl is not related to its inhibition of MAO B.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2801%2900028-1

7 January 2021

Apparent antioxidant effect of l-deprenyl on hydroxyl radical formation and nigral injury elicited by MPP+ in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2801%2900028-1

7 January 2021

Modulation of gene expression rather than monoamine oxidase inhibition: (-)-deprenyl-related compounds in controlling neurodegeneration

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2801%2900028-1

7 January 2021

(-) deprenyl induces activities of both superoxide dismutase and catalase but not of glutathione peroxidase in the striatum of young male rats

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2801%2900028-1

7 January 2021

R-deprenyl and R-2-heptyl-N-methylpropargylamine prevent apoptosis in cerebellar granule neurons induced by cytosine arabinoside but not low extracellular potassium.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2801%2900028-1

7 January 2021

Transfection-enforced Bcl-2 overexpression and an anti-Parkinson drug, rasagiline, prevent nuclear accumulation of glyceraldehyde-3-phosphate dehydrogenase induced by an endogenous dopaminergic neurotoxin, N-methyl(R)salsolinol

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2801%2900028-1

7 January 2021

10.1016/S1353-8020(01)00028-1

Identifiers

DOI

1 reference

22 September 2017

1 reference